An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)

Exclusion Criteria

• •Participants who were pregnant, may possibly be pregnant, or wish (including their partners) to became pregnant during the study period, or were lactating.
• •Participants who were unable to undergo all of the imaging procedures.
• •Participants who had an established diagnosis of CAD as confirmed by any of the following:
• •1. Previous myocardial infarction (MI);
• •2. Previous cardiac catheter angiography showing ≥50% stenosis;
• •3. Previous coronary revascularisation, such as percutaneous coronary intervention (PCI), thrombolysis or coronary artery bypass graft (CABG) placement.
• •Participants incapable of undergoing either exercise or pharmacological cardiac stress testing.
• •Participants who had a current illness or pathology that, in the opinion of the investigator, would pose a significant safety risk for the participant during cardiac stress testing.
• •Documented history of heart failure and/or cardiomyopathy and/or prior LV ejection fraction (LVEF) \<50%).
• •Participants scheduled for or planning to undergo any cardiac interventional procedures between enrolment and ICA.
• •Participants undergoing evaluation for heart transplantation or with history of heart transplantation.
• •Participants enrolled in another clinical study within the 30 days prior to being enrolled in this study or scheduled to participate in another clinical study during the 7-day follow-up period of this study.